Adage Capital Partners GP L.L.C. Reduces Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)

Adage Capital Partners GP L.L.C. reduced its holdings in Immunic, Inc. (NASDAQ:IMUX - Free Report) by 75.0% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,398,600 shares of the company's stock after selling 4,195,806 shares during the quarter. Adage Capital Partners GP L.L.C. owned 1.55% of Immunic worth $1,399,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Jane Street Group LLC grew its position in Immunic by 121.4% in the third quarter. Jane Street Group LLC now owns 70,299 shares of the company's stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. HB Wealth Management LLC bought a new position in shares of Immunic during the 4th quarter valued at about $81,000. State Street Corp raised its holdings in shares of Immunic by 7.5% during the 3rd quarter. State Street Corp now owns 167,145 shares of the company's stock valued at $276,000 after buying an additional 11,642 shares in the last quarter. Renaissance Technologies LLC lifted its position in Immunic by 45.6% in the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after buying an additional 177,542 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Immunic in the third quarter worth approximately $50,000. 51.82% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on IMUX. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Immunic in a research note on Thursday. B. Riley reissued a "buy" rating and set a $6.00 price objective on shares of Immunic in a research note on Wednesday, April 16th. William Blair started coverage on shares of Immunic in a research report on Tuesday, March 25th. They set an "outperform" rating for the company. D. Boral Capital restated a "buy" rating and issued a $17.00 price objective on shares of Immunic in a research report on Wednesday, April 30th. Finally, StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, Immunic has a consensus rating of "Buy" and a consensus target price of $13.20.

Immunic Stock Performance

Shares of IMUX traded up $0.01 during mid-day trading on Monday, hitting $1.16. 502,038 shares of the company traded hands, compared to its average volume of 694,255. The stock has a market cap of $111.15 million, a price-to-earnings ratio of -0.94 and a beta of 1.73. The stock has a 50-day moving average price of $1.08 and a two-hundred day moving average price of $1.11. Immunic, Inc. has a 1 year low of $0.83 and a 1 year high of $2.11.

Immunic Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.